JD Health International Inc. saw its stock price soar 5.20% during intraday trading on Thursday, reflecting significant positive investor sentiment.
The sharp rise appears to be driven by bullish analyst outlooks. Both UBS and HSBC maintained their Buy ratings on the stock, with UBS setting a price target of HK$70.70 and HSBC setting a target of HK$79.50. These reaffirmations of confidence from major financial institutions likely contributed to the strong buying pressure observed in the market.